Arshia Sadreddin, MD
Neurology · Antioch
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 7
Offices
7 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Hospitals listed: 057003 · California Pacific Medical Center - Mission Bernal · California Pacific Medical Center- Van Ness Campus · California Pacific Medical Ctr-Davies Campus Hosp. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Sadreddin’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A121600 · Current
Licensed to practise in California · since 2012 · expires 2028-06-30 · Ross University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- California Pacific Medical Center - Mission BernalSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.322, Oct 2024 – Sep 2025
- California Pacific Medical Center- Van Ness CampusSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.224, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.325, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.373, Oct 2024 – Sep 2025
- California Pacific Medical Ctr-Davies Campus HospSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · No emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.187, Oct 2024 – Sep 2025
See every measure and the patient survey for California Pacific Medical Center - Mission Bernal
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 3 the same, 3 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.322 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.19 to 2.28) · 336 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.47 to 1.27) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 163.19 (101.27 to 225.11) · 28 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.5 · 44 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.6 · 155 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.4 · 177 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.6 · 32 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 1,281 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.42) · 2,912 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.04 to 0.45) · 2,681 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.07 (1.81 to 6.33) · 787 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.61 (0 to 3.31) · 425 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.46 (0.79 to 4.12) · 755 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.36 (0 to 16.38) · 431 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.47 (1.38 to 9.55) · 401 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.7 (0.2 to 3.2) · 105 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 1.16) · 2,291 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 2.4 · 369 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.602 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.618 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 242 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 20.9 · 197 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 39.6 · 203 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 292 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 353 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.9 · 74 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 110 cases | No different | Jan 2024 – Dec 2024 |
What patients said (406 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 78% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 74% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for California Pacific Medical Center- Van Ness Campus
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.224 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.325 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.373 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.14 (0.3 to 1.97) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.81 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.86 (151.51 to 234.22) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 356 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.3 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 173 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.49) · 6,430 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.09 to 0.47) · 7,168 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.3 (1.5 to 5.09) · 2,196 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.47 (1.21 to 3.74) · 925 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.37 to 3.88) · 1,954 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.13 (6.06 to 14.2) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.26 (4.67 to 9.85) · 1,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.31 to 3.03) · 832 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 0.85) · 5,406 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.443 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.717 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 200 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 449 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.7 · 418 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 260 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.6 to 7.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (7.7 to 13.5) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 11 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.4 to 16.7) · 551 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 219 cases | No different | Jan 2024 – Dec 2024 |
What patients said (478 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for California Pacific Medical Ctr-Davies Campus Hosp
Behind the star rating — Deaths: 0 better, 4 the same, 0 worse of 4 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 4 the same, 1 worse of 5 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.187 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.02 (0 to 2.09) · 232 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.56 to 1.4) | No different | Jul 2022 – Jun 2024 |
| Death rate for heart failure patientsComplications and deaths | 10 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.1 · 106 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 257 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 721 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.26 (0.03 to 0.49) · 2,031 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.45) · 2,032 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.35 (0.94 to 5.76) · 419 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.41 (0 to 3) · 211 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.84 (1.24 to 4.44) · 414 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.95 (2.91 to 20.98) · 218 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.61 (1.47 to 9.75) · 198 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.74 (0.22 to 3.26) · 52 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.32 (0 to 1.28) · 1,461 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.6 · 58 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.756 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 91 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 65.3 · 84 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -26.6 · 115 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 142 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 55 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 25 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 312 cases | No different | Jan 2024 – Dec 2024 |
What patients said (602 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
Original Medicare doctor bills
$145,325
Medicare paid this office $145,325 for 227 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 186 | $65,191 | $163 |
| Botox | 13 | $43,364 | None |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, each additional 15 minutes with qualified health professional | 26 | $4,344 | $38 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 95 | $4,299 | $29 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 147 | $4,039 | $15 |
See all 10 services
| Long return visit (40+ min) | 186 | $65,191 | $163 |
| Botox | 13 | $43,364 | None |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, each additional 15 minutes with qualified health professional | 26 | $4,344 | $38 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 95 | $4,299 | $29 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 147 | $4,039 | $15 |
| Return visit (30+ min) | 29 | $3,805 | $115 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | 31 | $2,936 | $44 |
| New patient visit (60+ min) | 14 | $2,898 | $207 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $1,848 | $154 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator | 18 | $459 | $16 |
Procedures Medicare counted
| Skin biopsy | 1-10 | None |
Who their Medicare patients are
227 Original Medicare patients in 2024. Average age 76 · Women 48% · Also on Medicaid 19% · Health risk score 1.40. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 69% · Depression 39% · Diabetes 22% · Coronary heart disease 21% · Chronic kidney disease 20% · Dementia 19% · Atrial fibrillation 15% · Cancer 12% · Heart failure 11% · COPD 9% · Stroke 9%.
The office billed $518,478, Medicare allowed $187,817 and paid $145,325; for 9,958 services of 31 kinds; $43,364 of it was for drugs given in the office and $101,961 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 227 | 9,958 | 76 | 1.40 | $518,478 | $145,325 |
| 2023 | 276 | 7,053 | 76 | 1.48 | $406,831 | $121,727 |
| 2022 | 278 | 9,002 | 76 | 1.56 | $430,102 | $134,258 |
| 2021 | 281 | 7,208 | 75 | 1.62 | $425,033 | $127,724 |
| 2020 | 263 | 10,104 | 75 | 1.55 | $505,353 | $137,127 |
| 2019 | 257 | 7,722 | 76 | 1.54 | $429,710 | $114,579 |
| 2018 | 247 | 8,527 | 76 | 1.58 | $467,185 | $125,661 |
| 2017 | 252 | 11,313 | 74 | 1.53 | $504,093 | $136,776 |
| 2016 | 160 | 2,022 | 75 | 1.48 | $215,611 | $61,820 |
| 2015 | 163 | 2,634 | 74 | 1.64 | $258,881 | $71,262 |
| 2014 | 91 | 355 | 74 | 1.27 | $114,739 | $31,609 |
| 2013 | 188 | 6,563 | 71 | 1.47 | $340,714 | $95,795 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| Long return visit (40+ min) | 223 | $62,373 | $162 |
| Return visit (30+ min) | 40 | $5,394 | $115 |
| New patient visit (60+ min) | 20 | $3,979 | $199 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, each additional 15 minutes with qualified health professional | 20 | $3,854 | $40 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,360 | $157 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | 26 | $2,046 | $45 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 41 | $1,699 | $29 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator | 15 | $446 | $17 |
2022: 8 services
| Long return visit (40+ min) | 219 | $63,556 | $163 |
| Botox | 12 | $40,106 | None |
| New patient visit (60+ min) | 28 | $5,722 | $204 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, each additional 15 minutes with qualified health professional | 19 | $4,389 | $40 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $3,262 | $172 |
| Return visit (30+ min) | 29 | $2,633 | $91 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | 23 | $2,538 | $46 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 51 | $2,386 | $30 |
2021: 8 services
| Long return visit (40+ min) | 208 | $57,533 | $154 |
| Botox | 11 | $29,787 | None |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, each additional 15 minutes with qualified health professional | 18 | $9,529 | $40 |
| Return visit (30+ min) | 51 | $6,601 | $108 |
| New patient visit (60+ min) | 29 | $5,152 | $178 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 79 | $4,171 | $30 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $3,094 | $172 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | 19 | $3,005 | $46 |
2020: 9 services
| Botox | 17 | $43,251 | None |
| Long return visit (40+ min) | 161 | $34,909 | $123 |
| Return visit (30+ min) | 141 | $23,126 | $92 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, each additional 15 minutes with qualified health professional | 14 | $8,254 | $40 |
| Extended office or other outpatient service, first hour | 55 | $7,914 | $120 |
| New patient visit (60+ min) | 33 | $6,045 | $183 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 11 | $3,573 | $137 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | 17 | $2,897 | $47 |
| Extended patient service without direct patient contact, first hour | 13 | $1,965 | $103 |
2019: 7 services
| Long return visit (40+ min) | 186 | $34,216 | $118 |
| Return visit (30+ min) | 96 | $13,167 | $95 |
| Extended office or other outpatient service, first hour | 75 | $10,337 | $117 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, each additional 15 minutes with qualified health professional | 13 | $6,740 | $39 |
| New patient visit (60+ min) | 38 | $6,518 | $172 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | 14 | $2,447 | $44 |
| Extended patient service without direct patient contact, first hour | 11 | $1,112 | $101 |
2018: 5 services
| Long return visit (40+ min) | 177 | $37,296 | $121 |
| Botox | 13 | $37,279 | None |
| Return visit (30+ min) | 113 | $16,240 | $91 |
| New patient visit (60+ min) | 46 | $7,604 | $165 |
| Extended office or other outpatient service, first hour | 54 | $6,839 | $116 |
2017: 7 services
| Botox | 29 | $49,056 | None |
| Long return visit (40+ min) | 149 | $30,302 | $121 |
| Return visit (30+ min) | 142 | $23,909 | $91 |
| New patient visit (60+ min) | 54 | $9,131 | $169 |
| Extended office or other outpatient service, first hour | 35 | $4,330 | $117 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 19 | $4,215 | $128 |
| Short return visit (20+ min) | 12 | $1,453 | $69 |
2016: 4 services
| Long return visit (40+ min) | 104 | $24,751 | $135 |
| Return visit (30+ min) | 79 | $15,162 | $100 |
| New patient visit (60+ min) | 37 | $7,011 | $189 |
| Extended office or other outpatient service, first hour | 28 | $2,551 | $91 |
2015: 5 services
| Long return visit (40+ min) | 103 | $21,878 | $129 |
| Return visit (30+ min) | 102 | $20,805 | $95 |
| New patient visit (60+ min) | 59 | $10,603 | $180 |
| Short return visit (20+ min) | 19 | $1,709 | $66 |
| Extended office or other outpatient service, first hour | 17 | $1,532 | $90 |
2014: 4 services
| Long return visit (40+ min) | 64 | $14,698 | $131 |
| Return visit (30+ min) | 45 | $7,512 | $98 |
| New patient visit (60+ min) | 28 | $5,114 | $183 |
| Extended office or other outpatient service, first hour | 22 | $2,081 | $90 |
2013: 13 services
| Long return visit (40+ min) | 110 | $22,040 | $96 |
| Botox | 17 | $22,033 | None |
| Electronic analysis and programming of implanted complex deep brain neurostimulator generator system, first hour | 16 | $10,887 | $191 |
| Return visit (30+ min) | 79 | $10,454 | $78 |
| New patient visit (60+ min) | 28 | $3,957 | $141 |
| Electronic analysis and programming of implanted complex deep brain neurostimulator generator system | 12 | $2,475 | $82 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 16 | $2,449 | $153 |
| Injection of chemical for destruction of neck muscles | 11 | $2,223 | $106 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $1,868 | $78 |
| Extended office or other outpatient service, first hour | 18 | $1,570 | $75 |
| Short return visit (20+ min) | 16 | $1,557 | $54 |
| Muscle electrical test | 12 | $1,261 | $57 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $1,191 | $54 |
Medicaid work
$957 in 2023
Medicaid paid $957 for 25 billed services this clinician did in 2023, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 25 | $957 |
| 2023 | 25 | 1 | 12 | $957 |
| 2021 | 14 | 1 | 14 | $531 |
See the largest Medicaid services in earlier years
2021
| Long return visit (40+ min) | 14 | $531 |
Drugs they prescribed that Part D paid
$315,721
Pharmacies billed $315,721 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 713) in 2024. At or below the middle of the specialty; the typical neurology clinician is at 0%.
580 generic and 133 brand-name prescriptions · $315,721 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ingrezza | None | 12 | $85,971 | $7,164 |
| Rytary | Parkinson's | 51 | $69,856 | $1,370 |
| Carbidopa-Levodopa Er | None | 186 | $15,504 | $83 |
| Ongentys | None | 20 | $12,809 | $640 |
| Ajovy | None | 11 | $7,934 | $721 |
See all 15 drugs
| Ingrezza | None | 12 | $85,971 | $7,164 |
| Rytary | Parkinson's | 51 | $69,856 | $1,370 |
| Carbidopa-Levodopa Er | None | 186 | $15,504 | $83 |
| Ongentys | None | 20 | $12,809 | $640 |
| Ajovy | None | 11 | $7,934 | $721 |
| Carbidopa-Levodopa | None | 144 | $6,931 | $48 |
| Entacapone | None | 42 | $4,578 | $109 |
| Rivastigmine | None | 20 | $2,050 | $102 |
| Ropinirole Er | None | 11 | $1,685 | $153 |
| Memantine | None | 22 | $888 | $40 |
| Propranolol Hcl Er | None | 11 | $630 | $57 |
| Gabapentin | None | 20 | $345 | $17 |
| Donepezil | None | 27 | $257 | $10 |
| Propranolol | None | 15 | $190 | $13 |
| Escitalopram | None | 22 | $144 | $7 |
Year by year
| 2024 | 713 | 173 | 0% (0) | 19% | $315,721 |
| 2023 | 762 | 177 | 0% (0) | 21% | $274,472 |
| 2022 | 919 | 202 | 0% (0) | 26% | $468,535 |
| 2021 | 962 | 195 | 0% (0) | 26% | $723,332 |
| 2020 | 1,144 | 218 | 0% (0) | 21% | $808,609 |
| 2019 | 1,347 | 226 | 0% (0) | 14% | $554,768 |
| 2018 | 1,780 | 218 | 0% (0) | 14% | $512,515 |
| 2017 | 1,713 | 209 | None | 13% | $343,079 |
| 2016 | 1,282 | 148 | None | 15% | $243,074 |
| 2015 | 974 | 131 | 0% (0) | 18% | $124,591 |
| 2014 | 543 | 124 | None | 19% | $256,881 |
| 2013 | 1,594 | 153 | None | 26% | $735,797 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 10 drugs
| Rytary | Parkinson's | 70 | $91,522 | $1,307 |
| Ongentys | None | 46 | $32,896 | $715 |
| Carbidopa-Levodopa Er | None | 215 | $23,064 | $107 |
| Carbidopa-Levodopa | None | 171 | $14,557 | $85 |
| Entacapone | None | 27 | $9,101 | $337 |
| Pramipexole Dihydrochloride | None | 11 | $1,315 | $120 |
| Memantine | None | 13 | $920 | $71 |
| Amantadine | None | 14 | $907 | $65 |
| Donepezil | None | 33 | $640 | $19 |
| Gabapentin | None | 18 | $252 | $14 |
2022: 21 drugs
| Ingrezza | None | 16 | $111,742 | $6,984 |
| Rytary | Parkinson's | 98 | $101,775 | $1,039 |
| Ongentys | None | 47 | $29,806 | $634 |
| Neupro | None | 15 | $25,230 | $1,682 |
| Carbidopa-Levodopa | None | 233 | $23,057 | $99 |
| Gocovri | None | 11 | $18,463 | $1,678 |
| Carbidopa-Levodopa Er | None | 156 | $17,200 | $110 |
| Inbrija | None | 11 | $16,762 | $1,524 |
| Rasagiline Mesylate | None | 13 | $10,188 | $784 |
| Pramipexole Er | None | 14 | $5,122 | $366 |
| Entacapone | None | 26 | $4,354 | $167 |
| Selegiline | None | 11 | $1,713 | $156 |
| Ropinirole | None | 15 | $1,587 | $106 |
| Pregabalin | None | 12 | $896 | $75 |
| Memantine | None | 18 | $838 | $47 |
| Donepezil | None | 46 | $833 | $18 |
| Pramipexole Dihydrochloride | None | 29 | $774 | $27 |
| Mirtazapine | None | 14 | $631 | $45 |
| Escitalopram | None | 15 | $280 | $19 |
| Propranolol | None | 11 | $218 | $20 |
| Gabapentin | None | 11 | $169 | $15 |
2021: 20 drugs
| Ingrezza | None | 26 | $181,676 | $6,988 |
| Northera | None | 13 | $163,514 | $12,578 |
| Rytary | Parkinson's | 75 | $83,211 | $1,109 |
| Ongentys | None | 70 | $42,986 | $614 |
| Carbidopa-Levodopa | None | 258 | $35,961 | $139 |
| Inbrija | None | 11 | $33,816 | $3,074 |
| Neupro | None | 24 | $27,010 | $1,125 |
| Carbidopa-Levodopa Er | None | 110 | $15,188 | $138 |
| Rasagiline Mesylate | None | 14 | $7,869 | $562 |
| Selegiline | None | 13 | $1,995 | $153 |
| Pramipexole Dihydrochloride | None | 47 | $1,871 | $40 |
| Amantadine | None | 17 | $1,295 | $76 |
| Memantine | None | 16 | $910 | $57 |
| Ropinirole | None | 19 | $890 | $47 |
| Pregabalin | None | 13 | $698 | $54 |
| Donepezil | None | 27 | $493 | $18 |
| Propranolol | None | 14 | $430 | $31 |
| Escitalopram | None | 33 | $406 | $12 |
| Gabapentin | None | 16 | $224 | $14 |
| Citalopram Hbr | None | 11 | $77 | $7 |
2020: 21 drugs
| Northera | None | 20 | $344,118 | $17,206 |
| Rytary | Parkinson's | 92 | $86,104 | $936 |
| Carbidopa-Levodopa | None | 356 | $41,106 | $115 |
| Neupro | None | 40 | $35,794 | $895 |
| Inbrija | None | 17 | $35,168 | $2,069 |
| Carbidopa-Levodopa Er | None | 162 | $26,475 | $163 |
| Rasagiline Mesylate | None | 24 | $21,899 | $912 |
| Entacapone | None | 20 | $10,530 | $526 |
| Carbidopa | None | 16 | $7,981 | $499 |
| Pramipexole Dihydrochloride | None | 60 | $3,152 | $53 |
| Selegiline | None | 28 | $2,930 | $105 |
| Memantine | None | 15 | $1,211 | $81 |
| Amantadine | None | 11 | $1,095 | $100 |
| Donepezil | None | 28 | $838 | $30 |
| Propranolol | None | 24 | $828 | $34 |
| Primidone | None | 11 | $368 | $33 |
| Escitalopram | None | 30 | $360 | $12 |
| Ropinirole | None | 18 | $350 | $19 |
| Gabapentin | None | 16 | $331 | $21 |
| Sertraline | None | 12 | $119 | $10 |
| Citalopram Hbr | None | 12 | $84 | $7 |
2019: 20 drugs
| Northera | None | 12 | $189,408 | $15,784 |
| Rytary | Parkinson's | 73 | $58,405 | $800 |
| Carbidopa-Levodopa | None | 387 | $32,984 | $85 |
| Rasagiline Mesylate | None | 34 | $29,919 | $880 |
| Carbidopa-Levodopa Er | None | 232 | $28,298 | $122 |
| Neupro | None | 26 | $23,813 | $916 |
| Entacapone | None | 26 | $13,223 | $509 |
| Carbidopa | None | 17 | $9,469 | $557 |
| Selegiline | None | 56 | $7,054 | $126 |
| Pramipexole Dihydrochloride | None | 60 | $3,831 | $64 |
| Amantadine | None | 31 | $2,218 | $72 |
| Donepezil | None | 72 | $1,195 | $17 |
| Propranolol Hcl Er | None | 14 | $1,032 | $74 |
| Propranolol | None | 23 | $743 | $32 |
| Ropinirole | None | 15 | $690 | $46 |
| Gabapentin | None | 36 | $674 | $19 |
| Sertraline | None | 27 | $265 | $10 |
| Mirtazapine | None | 16 | $237 | $15 |
| Escitalopram | None | 22 | $234 | $11 |
| Topiramate | None | 11 | $219 | $20 |
2018: 27 drugs
| Rytary | Parkinson's | 90 | $77,050 | $856 |
| Carbidopa-Levodopa Er | None | 300 | $43,489 | $145 |
| Carbidopa-Levodopa | None | 467 | $33,739 | $72 |
| Entacapone | None | 50 | $31,550 | $631 |
| Rasagiline Mesylate | None | 31 | $31,477 | $1,015 |
| Neupro | None | 19 | $21,437 | $1,128 |
| Carbidopa-Levodopa-Entacapone | None | 32 | $13,033 | $407 |
| Selegiline | None | 66 | $11,935 | $181 |
| Xadago | None | 14 | $10,607 | $758 |
| Pramipexole Er | None | 16 | $7,997 | $500 |
| Pramipexole Dihydrochloride | None | 56 | $3,765 | $67 |
| Amantadine | None | 42 | $2,938 | $70 |
| Ropinirole | None | 35 | $1,586 | $45 |
| Propranolol Hcl Er | None | 17 | $1,505 | $89 |
| Duloxetine | None | 26 | $1,251 | $48 |
| Propranolol | None | 43 | $1,210 | $28 |
| Donepezil | None | 56 | $1,119 | $20 |
| Gabapentin | None | 75 | $887 | $12 |
| Primidone | None | 26 | $644 | $25 |
| Escitalopram | None | 39 | $524 | $13 |
| Topiramate | None | 28 | $430 | $15 |
| Rizatriptan | None | 20 | $393 | $20 |
| Quetiapine | None | 27 | $362 | $13 |
| Sertraline | None | 42 | $338 | $8 |
| Trihexyphenidyl | None | 15 | $218 | $15 |
| Baclofen | None | 17 | $192 | $11 |
| Mirtazapine | None | 13 | $107 | $8 |
2017: 26 drugs
| Rytary | Parkinson's | 36 | $41,025 | $1,140 |
| Carbidopa-Levodopa Er | None | 318 | $33,043 | $104 |
| Neupro | None | 40 | $32,905 | $823 |
| Carbidopa-Levodopa | None | 401 | $26,467 | $66 |
| Rasagiline Mesylate | None | 20 | $25,134 | $1,257 |
| Entacapone | None | 57 | $22,583 | $396 |
| Carbidopa-Levodopa-Entacapone | None | 23 | $13,583 | $591 |
| Selegiline | None | 57 | $10,375 | $182 |
| Pramipexole Er | None | 11 | $5,991 | $545 |
| Namenda | None | 12 | $4,863 | $405 |
| Amantadine | None | 26 | $2,960 | $114 |
| Pramipexole Dihydrochloride | None | 53 | $2,738 | $52 |
| Gabapentin | None | 91 | $1,677 | $18 |
| Duloxetine | None | 26 | $1,653 | $64 |
| Propranolol | None | 62 | $1,525 | $25 |
| Propranolol Hcl Er | None | 12 | $1,412 | $118 |
| Primidone | None | 53 | $849 | $16 |
| Donepezil | None | 59 | $741 | $13 |
| Ropinirole | None | 16 | $447 | $28 |
| Topiramate | None | 33 | $425 | $13 |
| Escitalopram | None | 41 | $388 | $9 |
| Levetiracetam | None | 16 | $387 | $24 |
| Sertraline | None | 62 | $353 | $6 |
| Quetiapine | None | 15 | $138 | $9 |
| Mirtazapine | None | 13 | $54 | $4 |
| Alprazolam | None | 15 | $40 | $3 |
2016: 26 drugs
| Azilect | None | 62 | $50,981 | $822 |
| Carbidopa-Levodopa Er | None | 247 | $17,374 | $70 |
| Carbidopa-Levodopa | None | 348 | $15,451 | $44 |
| Entacapone | None | 43 | $15,003 | $349 |
| Neupro | None | 17 | $13,182 | $775 |
| Rytary | Parkinson's | 14 | $11,773 | $841 |
| Pramipexole Er | None | 21 | $10,417 | $496 |
| Selegiline | None | 37 | $5,018 | $136 |
| Namenda | None | 12 | $4,533 | $378 |
| Myrbetriq | None | 11 | $3,879 | $353 |
| Amantadine | None | 18 | $2,567 | $143 |
| Propranolol Hcl Er | None | 28 | $2,532 | $90 |
| Pramipexole Dihydrochloride | None | 39 | $1,931 | $50 |
| Duloxetine | None | 12 | $1,624 | $135 |
| Gabapentin | None | 39 | $885 | $23 |
| Primidone | None | 36 | $778 | $22 |
| Propranolol | None | 21 | $771 | $37 |
| Levetiracetam | None | 21 | $482 | $23 |
| Mirtazapine | None | 17 | $442 | $26 |
| Topiramate | None | 31 | $431 | $14 |
| Donepezil | None | 25 | $365 | $15 |
| Trihexyphenidyl | None | 12 | $261 | $22 |
| Sertraline | None | 25 | $178 | $7 |
| Quetiapine | None | 12 | $136 | $11 |
| Diazepam | None | 14 | $72 | $5 |
| Citalopram Hbr | None | 21 | $63 | $3 |
2015: 18 drugs
| Azilect | 58 | $36,386 | $627 |
| Entacapone | 37 | $15,567 | $421 |
| Neupro | 25 | $14,276 | $571 |
| Carbidopa-Levodopa Er | 162 | $12,407 | $77 |
| Carbidopa-Levodopa | 260 | $11,303 | $43 |
| Namenda | 22 | $6,788 | $309 |
| Selegiline | 22 | $2,571 | $117 |
| Pramipexole Dihydrochloride | 47 | $2,334 | $50 |
| Amantadine | 18 | $2,184 | $121 |
| Propranolol Hcl Er | 16 | $985 | $62 |
| Gabapentin | 45 | $891 | $20 |
| Propranolol | 20 | $477 | $24 |
| Mirtazapine | 24 | $414 | $17 |
| Donepezil | 23 | $251 | $11 |
| Topiramate | 18 | $220 | $12 |
| Divalproex | 12 | $166 | $14 |
| Clonazepam | 11 | $88 | $8 |
| Diazepam | 17 | $65 | $4 |
2014: 14 drugs
| Xenazine | 25 | $185,418 | $7,417 |
| Azilect | 26 | $18,823 | $724 |
| Carbidopa-Levodopa | 129 | $9,369 | $73 |
| Entacapone | 17 | $7,725 | $454 |
| Neupro | 13 | $7,527 | $579 |
| Carbidopa-Levodopa Er | 82 | $5,397 | $66 |
| Amantadine | 23 | $2,261 | $98 |
| Midodrine | 14 | $1,309 | $94 |
| Pramipexole Dihydrochloride | 13 | $806 | $62 |
| Gabapentin | 27 | $718 | $27 |
| Sertraline | 12 | $189 | $16 |
| Clonazepam | 23 | $166 | $7 |
| Donepezil | 11 | $155 | $14 |
| Omeprazole | 13 | $118 | $9 |
2013: 31 drugs
| Xenazine | 84 | $550,439 | $6,553 |
| Azilect | 39 | $26,131 | $670 |
| Carbidopa-Levodopa | 315 | $22,569 | $72 |
| Carbidopa-Levodopa-Entacapone | 16 | $13,004 | $813 |
| Neupro | 32 | $12,931 | $404 |
| Lodosyn | 28 | $9,458 | $338 |
| Cymbalta | 27 | $8,541 | $316 |
| Amantadine | 87 | $8,194 | $94 |
| Namenda | 23 | $7,560 | $329 |
| Entacapone | 15 | $5,935 | $396 |
| Carbidopa-Levodopa Er | 87 | $5,347 | $61 |
| Pramipexole Dihydrochloride | 44 | $3,932 | $89 |
| Midodrine | 49 | $3,170 | $65 |
| Levetiracetam | 27 | $2,166 | $80 |
| Ropinirole | 23 | $1,538 | $67 |
| Clonazepam | 94 | $1,262 | $13 |
| Sertraline | 102 | $1,029 | $10 |
| Gabapentin | 41 | $939 | $23 |
| Donepezil | 37 | $754 | $20 |
| Quetiapine | 27 | $753 | $28 |
| Venlafaxine | 11 | $644 | $59 |
| Trihexyphenidyl | 34 | $533 | $16 |
| Oxybutynin Chloride | 16 | $393 | $25 |
| Haloperidol | 18 | $373 | $21 |
| Lorazepam | 23 | $341 | $15 |
| Primidone | 18 | $328 | $18 |
| Topiramate | 12 | $262 | $22 |
| Benztropine Mesylate | 25 | $198 | $8 |
| Alprazolam | 16 | $154 | $10 |
| Omeprazole | 12 | $149 | $12 |
| Propranolol | 21 | $126 | $6 |
Money from drug and device companies
$448 in 2025
| 2025 | 2 | 10 | None | $448 |
| 2024 | 7 | 24 | None | $2,146 |
| 2023 | 4 | 20 | $5,600 | $8,164 |
| 2022 | 6 | 25 | $18,435 | $20,707 |
| 2021 | 10 | 49 | $19,100 | $22,570 |
| 2020 | 8 | 31 | $14,350 | $16,086 |
| 2019 | 19 | 70 | $22,866 | $25,269 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boston Scientific | General - Dbs | $394 | 9 payments
|
| Abbvie | Vyalev | $53 | 1 payment
|
See all 10 published payments
| Boston Scientific | Meals · 2025-11-04 | Vercise | $32 |
| Abbvie | Meals · 2025-10-06 | Vyalev | $53 |
| Boston Scientific | Meals · 2025-09-03 | Vercise | $30 |
| Boston Scientific | Meals · 2025-06-03 | General - Dbs | $60 |
| Boston Scientific | Meals · 2025-05-06 | General - Dbs | $45 |
| Boston Scientific | Meals · 2025-04-09 | General - Dbs | $52 |
| Boston Scientific | Meals · 2025-04-01 | General - Dbs | $57 |
| Boston Scientific | Meals · 2025-03-04 | Vercise | $39 |
| Boston Scientific | Meals · 2025-02-04 | Vercise | $40 |
| Boston Scientific | Meals · 2025-01-07 | Vercise | $39 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,146
| Amneal Pharmaceuticals | Ongentys 50mg Capsules 30 | $1,425 | 3 payments
|
| Boston Scientific | Vercise | $291 | 7 payments
|
| Abbvie | Botox | $188 | 7 payments
|
| Medtronic | Percept PC Brainsense | $106 | 2 payments
|
| Abbott Laboratories | Infinity | $57 | 2 payments
|
| Neurocrine Biosciences | Ingrezza | $55 | 2 payments
|
| Acorda Therapeutics | Inbrija | $24 | 1 payment
|
2023: $8,164
| Boston Scientific | Vercise | $7,699 | 8 payments
|
| Medtronic | Percept PC Brainsense | $306 | 6 payments
|
| Neurocrine Biosciences | Ongentys | $88 | 3 payments
|
| AbbVie | Botox | $70 | 3 payments
|
2022: $20,707
| Neurocrine BioSciences | Ingrezza | $19,850 | 17 payments
|
| Acorda Therapeutics | Inbrija | $421 | 2 payments
|
| Boston Scientific | Vercise | $325 | 1 payment
|
| Medtronic | Percept PC Brainsense | $47 | 2 payments
|
| Sunovion Pharmaceuticals | Kynmobi | $43 | 2 payments
|
| Abbvie | Botox | $20 | 1 payment
|
2021: $22,570
| Neurocrine Biosciences | Ingrezza | $10,712 | 27 payments
|
| Acorda Therapeutics | Inbrija | $9,865 | 6 payments
|
| Boston Scientific | Vercise | $1,795 | 7 payments
|
| SK Life Science | None | $71 | 3 payments
|
| Teva Pharmaceuticals USA | Ajovy | $24 | 1 payment
|
| Biohaven Pharmaceuticals | Nurtec Odt | $24 | 1 payment
|
| Kyowa Kirin | Nourianz | $21 | 1 payment
|
| Ucb | Neupro | $20 | 1 payment
|
| Allergan | Botox | $20 | 1 payment
|
| Amgen | Aimovig | $19 | 1 payment
|
2020: $16,086
| Acorda Therapeutics | Inbrija | $8,562 | 11 payments
|
| Neurocrine Biosciences | Ingrezza | $7,371 | 13 payments
|
| Boston Scientific | General - Dbs | $41 | 2 payments
|
| Adamas Pharmaceuticals | Gocovri | $38 | 1 payment
|
| SK Life Science | None | $22 | 1 payment
|
| Medtronic USA | Activa | $21 | 1 payment
|
| Kyowa Kirin | Nourianz | $16 | 1 payment
|
| Allergan | Botox | $14 | 1 payment
|
2019: $25,269
| Neurocrine Biosciences | Ingrezza | $14,591 | 21 payments
|
| Acorda Therapeutics | Inbrija | $9,054 | 5 payments
|
| Medtronic USA | Activa | $957 | 12 payments
|
| Eisai | Fycompa | $69 | 2 payments
|
| Avanir Pharmaceuticals | Nuedexta | $62 | 3 payments
|
| LivaNova USA | Vns Therapy | $61 | 3 payments
|
| Adamas Pharmaceuticals | Gocovri | $52 | 2 payments
|
| Allergan | Botox | $49 | 3 payments
|
| Teva Pharmaceuticals USA | Ajovy | $49 | 2 payments
|
| Amgen | Aimovig | $48 | 2 payments
|
| Bausch Health US | Migranal | $46 | 3 payments
|
| Lilly USA | Emgality | $43 | 2 payments
|
| Novartis Pharmaceuticals | Aimovig | $43 | 2 payments
|
| US WorldMeds | Xadago | $43 | 2 payments
|
| Ucb | Neupro | $38 | 2 payments
|
| Aquestive Therapeutics | Sympazan | $20 | 1 payment
|
| Amneal Pharmaceuticals | Rytary | $17 | 1 payment
|
| Greenwich Biosciences | Epidiolex | $16 | 1 payment
|
| Supernus Pharmaceuticals | Trokendi Xr | $12 | 1 payment
|
Professional record
- NPI
- 1033308903
- Licence
- AZ 41357, CA A121600California A121600: Current · expires 2028-06-30
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- AZ 439617
- Taxonomy
- Neurology (2084N0400X)
- Mailing address
- 2350 W El Camino Real Fl 2, Mountain View, CA, 94040
- NPI first listed
- 2007-10-17
- NPI last updated
- 2018-07-30
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 240 W Thomas Rd, Phoenix, AZ, 85013